At-home Leqembi starting treatment is expected to become available in the United States in late August 2026. The FDA approved Leqembi IQLIK for initiation treatment on July 13, 2026, and manufacturer Eisai announced the late-August launch schedule. For example, an eligible patient diagnosed in September may be able to start weekly injections instead of traveling to an infusion center every two weeks, provided the prescription, insurance authorization, specialty-pharmacy delivery, and required medical evaluations are complete. [FDA approval information](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment) “Available at home” does not mean that every patient can administer the first dose independently. At least two consecutive doses must be given under the direct guidance of a healthcare provider.
The clinician then decides whether the patient or caregiver can safely handle subsequent injections. Some memory clinics may therefore continue using office-based injections during the early weeks, particularly when a patient has impaired dexterity, difficulty following multistep instructions, or no reliable caregiver. Leqembi, also known as lecanemab-irmb, is not a cure and does not restore memories already lost. It is an anti-amyloid treatment intended to slow disease progression in people at the mild cognitive impairment or mild dementia stage of Alzheimer’s disease. Moving administration into the home may reduce infusion-center travel, but it does not remove the need for specialist oversight, brain scans, safety monitoring, or ongoing decisions about whether treatment remains appropriate.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When Will At-Home Leqembi Starting Treatment Be Available to Alzheimer’s Patients?
- How At-Home Leqembi IQLIK Starting Treatment Works
- Who Is Eligible for At-Home Leqembi Treatment?
- How Families Can Prepare for At-Home Leqembi Starting Treatment
- ARIA, MRI Monitoring, and Other Safety Issues
- Medicare and Insurance Access for At-Home Leqembi
- Storage and Weekly Injection Logistics
- Frequently Asked Questions
When Will At-Home Leqembi Starting Treatment Be Available to Alzheimer’s Patients?
The FDA approval is already in place, but the planned U.S. commercial launch is late August 2026. That distinction matters: regulatory approval permits the product to be marketed, while commercial availability depends on manufacturing, distribution through specialty pharmacies, clinic readiness, and insurers adding the new starting regimen to their coverage systems. Eisai has said patients will receive initiation-dose Leqembi IQLIK through a specialty pharmacy. [Eisai’s launch announcement](https://media-us.eisai.com/2026-07-13-FDA-Approves-LEQEMBI-IQLIK-R-lecanemab-irmb-Subcutaneous-Injection-as-an-Initiation-Dose-for-Early-Alzheimers-Disease) Access may not begin everywhere on the same day.
A major academic memory center may establish prescribing and training procedures quickly, while a smaller neurology practice may need additional time to coordinate specialty-pharmacy shipments, MRI scheduling, staff education, and emergency protocols. Insurance prior authorization can also delay an individual patient’s start even after pharmacies have the product. Patients who need treatment before the home formulation becomes accessible can discuss the existing intravenous regimen with their clinicians. The comparison is not simply “start now” versus “wait for injections”: delaying disease-modifying treatment may have consequences, while starting intravenously introduces travel and infusion demands. The choice requires an individualized discussion rather than postponing treatment solely for convenience.
How At-Home Leqembi IQLIK Starting Treatment Works
During the first 18 months, the approved subcutaneous starting dose is 500 milligrams once weekly. Each full dose requires two single-use 250-milligram autoinjectors administered one immediately after the other. Each injection takes about 15 seconds. After at least two consecutive doses under a healthcare provider’s direct guidance, the clinician may authorize the patient or caregiver to continue administering the medicine outside the clinic. [Leqembi dosing information](https://www.leqembihcp.com/en/dosing) The alternative starting regimen is an intravenous dose of 10 milligrams per kilogram every two weeks, delivered during an infusion lasting approximately one hour.
The home option eliminates IV placement and most infusion-center visits, but it replaces twice-monthly appointments with a weekly responsibility. A caregiver who finds two short injections manageable may prefer IQLIK, while another family may value having nursing staff administer and document every IV dose. There is an important evidence limitation. The subcutaneous formulation was not evaluated in a separate, large clinical-outcome trial equivalent to the pivotal IV studies. The FDA based its effectiveness on the established clinical benefits of intravenous Leqembi, together with evidence that subcutaneous dosing produces comparable drug exposure and similar amyloid-plaque reduction. families should not interpret the autoinjector’s convenience as evidence that it is more effective than IV treatment.
Who Is Eligible for At-Home Leqembi Treatment?
Leqembi should be started in adults with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia—the stages represented in the clinical trials. A diagnosis of dementia by itself is insufficient. The presence of beta-amyloid pathology must be confirmed, generally through an amyloid PET scan or an appropriate cerebrospinal-fluid test, and clinicians must evaluate whether symptoms and test findings are consistent with Alzheimer’s disease. Consider a person who still lives independently but has increasing difficulty managing appointments and bills.
If cognitive testing shows mild impairment and an amyloid test is positive, that person may fit the treatment population. A person who needs extensive help with dressing, eating, and other basic activities because of more advanced dementia would not match the population in which Leqembi was initiated during clinical trials, even if amyloid is present. Eligibility for the medicine and suitability for home administration are separate decisions. A patient may qualify medically but be unable to use an autoinjector consistently because of tremor, poor vision, memory impairment, or anxiety about injections. In that situation, a dependable caregiver might administer the doses, or the clinical team may recommend supervised injections or IV infusions instead.
How Families Can Prepare for At-Home Leqembi Starting Treatment
Families considering the home regimen can begin by asking the treating neurologist or memory specialist whether the practice will prescribe initiation-dose Leqembi IQLIK after its launch. Useful questions include who will supervise the first two doses, which specialty pharmacy will ship the medicine, how delivery temperatures will be managed, and whom the family should call after hours if a reaction or neurological symptom occurs. The required medical workup should not be postponed while waiting for pharmacy availability. Clinicians must confirm amyloid pathology, obtain a recent baseline brain MRI, review the patient’s medications and bleeding risks, and discuss testing for the APOE ε4 gene variant.
Insurance authorization may require copies of the cognitive assessment, amyloid result, MRI report, diagnosis, and treatment plan. The practical tradeoff is weekly home responsibility versus less frequent clinic administration. A family living two hours from an infusion center may save substantial travel time with home injections. However, the caregiver must receive shipments, refrigerate the medicine correctly, track weekly doses, inspect both devices, administer two injections, and dispose of the used autoinjectors safely. A written dosing calendar and a backup caregiver can reduce the risk of missed or duplicated doses.
ARIA, MRI Monitoring, and Other Safety Issues
At-home dosing does not make Leqembi a low-monitoring treatment. Leqembi can cause amyloid-related imaging abnormalities, or ARIA, involving brain swelling or bleeding. ARIA frequently causes no noticeable symptoms and may be detected only on MRI, but serious, life-threatening, and fatal cases can occur. Warning symptoms include headache, confusion, dizziness, vision changes, nausea, difficulty walking, seizures, difficulty speaking, and muscle weakness. Anyone developing these symptoms during treatment needs prompt medical evaluation. [FDA safety information](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment) A baseline MRI is required, followed by scheduled MRIs during treatment.
Current dosing guidance calls for scans after months one, two, three, and six, generally within approximately one week before the relevant dose. Additional imaging may be needed when symptoms suggest ARIA or when a scheduled scan reveals an abnormality. A patient administering medicine in a rural home may therefore avoid infusion travel but still need access to timely MRI scanning and a clinician experienced in interpreting ARIA. People with two copies of the APOE ε4 variant have a higher risk of ARIA than people with one copy or no copies. Testing should be discussed before treatment, including what the genetic result may mean for the patient and biological relatives. Extra caution is also required for people taking anticoagulants or other medicines that affect clotting. Because ARIA symptoms can resemble a stroke, patients should carry information identifying them as Leqembi recipients so emergency clinicians can consider both conditions before using clot-dissolving treatment.
Medicare and Insurance Access for At-Home Leqembi
FDA approval does not guarantee immediate or identical coverage. Medicare’s national policy covers traditionally approved anti-amyloid antibodies under Coverage with Evidence Development for eligible beneficiaries with mild cognitive impairment or mild Alzheimer’s dementia and confirmed amyloid pathology. The prescribing clinician must participate in a qualifying study or registry and provide appropriate follow-up care.
[CMS coverage requirements](https://www.cms.gov/medicare/coverage/coverage-evidence-development/monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease-ad) For example, a Medicare beneficiary who qualifies clinically may still encounter separate authorization questions involving the medicine, specialty-pharmacy shipment, supervised training doses, amyloid testing, and MRIs. Private insurers and Medicare Advantage plans may apply their own documentation and network rules. Families should request a written benefits review covering the new 500-milligram initiation regimen rather than assuming that approval of IV Leqembi or the older maintenance autoinjector automatically establishes coverage.
Storage and Weekly Injection Logistics
Leqembi IQLIK autoinjectors must ordinarily be refrigerated at 36°F to 46°F and protected from light in their original carton. They must not be frozen or shaken. The medication may remain in its original carton at room temperature, no warmer than 77°F, for up to 14 days, but it must not be returned to the refrigerator after being brought to room temperature.
For example, a carton accidentally left in a hot car should not be used without instructions from the specialty pharmacist or prescribing team. [FDA-approved Medication Guide and Instructions for Use](https://www.leqembi.com/-/media/Files/Leqembi/Medication-Guide.pdf) Before a dose, both starting-dose autoinjectors are left at room temperature for 20 minutes without using an external heat source. The injections may be given in the front of the thighs or abdomen, avoiding the two-inch area around the navel; a caregiver or healthcare provider may also use the back of the upper arm. The second autoinjector is used immediately after the first at a site at least one inch away, and both used devices go into an FDA-cleared sharps container rather than household trash.
Frequently Asked Questions
Can a patient give the first Leqembi IQLIK dose alone at home?
Not under the approved instructions. At least two consecutive doses must be administered under the direct guidance of a healthcare provider. The clinician then determines whether the patient or caregiver can administer later doses appropriately.
Can someone already receiving IV Leqembi switch to the at-home formulation before 18 months?
The approved dosing options allow patients in the initiation phase to switch from IV treatment to weekly subcutaneous IQLIK. Current guidance places the first subcutaneous dose one week after the last Leqembi infusion, but the prescriber must direct the transition.
Does at-home Leqembi eliminate infusion-center visits and MRIs?
It may eliminate most infusion visits, but it does not eliminate clinical appointments or MRI monitoring. Baseline and scheduled follow-up scans remain necessary because ARIA can occur without symptoms.
Is Leqembi IQLIK intended for moderate or severe Alzheimer’s dementia?
Treatment should be initiated in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Safety and effectiveness have not been established for beginning treatment at more advanced stages.
What happens if a weekly injection is missed?
FDA-approved instructions state that a missed subcutaneous dose should be given as soon as possible, up to six days after the missed dose, followed by the next injection on the original scheduled day. Patients should contact the prescribing team if there is uncertainty or if more than six days have passed.
